» Articles » PMID: 36743892

Construction and Validation of a Nomogram Model to Predict the Overall Survival Rate of Esophageal Cancer Patients Receiving Neoadjuvant Chemotherapy: A Population-based Study

Overview
Journal Front Surg
Specialty General Surgery
Date 2023 Feb 6
PMID 36743892
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The development of neoadjuvant chemotherapy(nCT) improves the overall survival (OS) of patients with esophageal cancer(EC). The aim of this study was to determine the independent prognostic factors of EC patients receiving nCT, and to construct a nomogram model for predicting OS.

Method: This retrospective analysis was conducted from the National Cancer Institute's Surveillance Epidemiology and End Results, Clinicopathological data of patients with EC who received nCT from 2004 to 2015. The included patients were randomly divided into the training cohort and the validation cohort. Univariate and multivariate Cox proportional hazards models were used to analyze the patients in the training cohort to determine the independent prognostic factors. Based on the independent prognostic variables, nomogram models for 1-year, 2-year and 3-year OS were constructed. The receiver operating characteristic (ROC) and area under curve (AUC) were used to evaluate the discriminative ability. The calibration curves, decision curve analysis (DCA) and Kaplan-Meier (K-M) survival analysis were used to evaluate the predictive accuracy and clinical application value.

Results: A total of 2,493 patients were enrolled, with 1,748 patients in the training cohort and 745 patients in the validation cohort. Gender, marital status, tumor pathological grade, T stage, N stage, and M stage were identified as independent prognostic factor ( < 0.05). A novel nomogram model was constructed. ROC curve analysis revealed that the model had moderate predictive performance, which was better than that of the AJCC TNM staging system.The calibration curves showed a high agreement between the actual observed values and the predicted values. The DCA suggested that the newly constructed prediction model had good clinical application value. K-M survival analysis showed that the model was helpful to accurately distinguish the prognosis of patients with different risk levels.

Conclusions: Gender, tumor pathological grade, marital status, T stage, N stage and M stage were identified as independent prognostic factors for overall survival of patients with esophageal cancer who received neoadjuvant chemotherapy. A nomogram prediction model was established, which was helpful to accurately and reliably predict the overall survival rate of patients with esophageal cancer who received neoadjuvant chemotherapy at 1, 2 and 3 years.

Citing Articles

Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.

van Eijck C, Mustafa D, Vadgama D, de Miranda N, Groot Koerkamp B, van Tienhoven G Gut. 2023; 73(2):311-324.

PMID: 37709493 PMC: 10850691. DOI: 10.1136/gutjnl-2023-330480.

References
1.
Allum W, Stenning S, Bancewicz J, Clark P, Langley R . Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27(30):5062-7. DOI: 10.1200/JCO.2009.22.2083. View

2.
Cheng S, Yang L, Dai X, Wang J, Han X . The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database. BMC Cancer. 2021; 21(1):1057. PMC: 8465786. DOI: 10.1186/s12885-021-08802-8. View

3.
Shang Q, Yang Y, Hu W, Yuan Y, Ji A, Chen L . Prognostic significance and role of thoracic lymph node metastasis based on Chinese expert consensus in esophageal cancer. Ann Transl Med. 2019; 7(16):381. PMC: 6736806. DOI: 10.21037/atm.2019.07.63. View

4.
Kattan M, Hess K, Amin M, Lu Y, Moons K, Gershenwald J . American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016; 66(5):370-4. PMC: 4955656. DOI: 10.3322/caac.21339. View

5.
Huang Z, Wang Y, Wu Y, Guo C, Li W, Kong Q . A Novel Tool to Predict the Overall Survival of High-Grade Osteosarcoma Patients after Neoadjuvant Chemotherapy: A Large Population-Based Cohort Study. J Oncol. 2022; 2022:8189610. PMC: 9338873. DOI: 10.1155/2022/8189610. View